Companies › Dren Bio
2 active drug programs in 4 registered trials: 4 Phase 1; Oncology, Hematology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dibotatug (DR-01) non-fucosylated human IgG1 monoclonal antibody | – | Phase 1 | LGLL - Large Granular Lymphocytic Leukemia; Alopecia Areata; Bone Marrow Failure Syndromes | Dec 2026 |
| DR-0202 Bispecific antibody | – | Phase 1 | Triple Negative Breast Cancer | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05475925 | Dibotatug (DR-01) | Phase 1 | LGLL - Large Granular Lymphocytic Leukemia | Oncology | Dec 2026 |
| NCT06602232 | Dibotatug (DR-01) | Phase 1 | Alopecia Areata | Immunology | May 2027 |
| NCT06999187 | DR-0202 | Phase 1 | Triple Negative Breast Cancer | Oncology | Jul 2027 |
| NCT07712562 | Dibotatug (DR-01) | Phase 1 | Bone Marrow Failure Syndromes | Hematology | Apr 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.